Pharmacotherapy of Basal Cell Carcinoma, Anogenital Warts, and Actinic Keratoses: Focus on Topical Imiquimod

2011 ◽  
Vol 3 ◽  
pp. 13-27
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Anogenital Warts ◽  
Actinic Keratoses ◽  
Topical Imiquimod

Emerging medical treatments for actinic keratoses, squamous cell carcinoma and basal cell carcinoma

2012 ◽  
Vol 2 (9) ◽  
pp. 909-921 ◽  
Author(s):  
Nasreen Ghuznavi ◽  
Nadia F Nocera ◽  
Andrew R Guajardo ◽  
Jeffrey M Weinberg
Keyword(s):  
Squamous Cell Carcinoma ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Basal Cell ◽  
Medical Treatments ◽  
Actinic Keratoses

Treatment of infiltrating basal cell carcinoma with the combination of intralesional IFNα-2b and topical imiquimod 5% cream

2009 ◽  
Vol 48 (2) ◽  
pp. 214-215 ◽  
Author(s):  
Aysegul Turan ◽  
Hayriye Saricaoglu ◽  
Emel Bulbul Baskan ◽  
Semra Cikman Toker ◽  
Sukran Tunali
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Imiquimod

Viral and Nonviral Uses of Imiquimod: A Review

2004 ◽  
Vol 8 (5) ◽  
pp. 338-352 ◽  
Author(s):  
Aditya K. Gupta ◽  
Andrea M. Cherman ◽  
Stephen K. Tyring
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Skin Diseases ◽  
Interleukin 12 ◽  
Antitumor Effects ◽  
Skin Reactions ◽  
Local Skin ◽  
Actinic Keratoses ◽  
Skin Conditions

Background: Imiquimod is a topical immunomodulator that is indicated for the treatment of external genital and perianal warts. This drug has been recently approved for the treatment of actinic keratoses and superficial basal cell carcinoma. There is a growing body of evidence for its effectiveness in treating a variety of other skin conditions. Objective: This review examines the role of imiquimod 5% cream in the treatment of skin diseases such as actinic keratoses, basal cell carcinoma, Bowen's disease, lentigo maligna, and extramammary Paget's disease. Methods: Published literature containing the words “Imiquimod” or “Aldara” was reviewed and summarized. Results: This agent has demonstrated indirect antiviral and antitumor effects in animal models. Although the exact mechanism of action is unknown, imiquimod is an agonist for toll-like receptor (TLR) 7 and is thought to act by inducing cytokines, such as interferon alpha (IFN-α), interleukin-12 (IL-12), and tumor necrosis factor alpha (TNF-α). These cytokines trigger the immune system to recognize the presence of a viral infection or tumor and the associated lesion is ultimately eradicated. Side effects are generally well tolerated with local skin reactions reported most frequently. Conclusion: Imiquimod has been shown to be a safe and effective treatment for a variety of skin conditions.

Sign in / Sign up

Export Citation Format

Share Document